Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Journal Articles and Abstracts

6-1-2018

Secukinumab improves active psoriatic arthritis
symptoms and inhibits radiographic progression:
primary results from the randomised, double-blind,
phase III FUTURE 5 study.
Philip Mease
Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, Washington, USA.

Désirée van der Heijde
Robert Landewé
Shephard Mpofu
Proton Rahman
See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Orthopedics Commons, and the Rheumatology Commons
Recommended Citation
Mease, Philip; van der Heijde, Désirée; Landewé, Robert; Mpofu, Shephard; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher,
Elke; Navarra, Sandra; Meiser, Karin; Readie, Aimee; Pricop, Luminita; and Abrams, Ken, "Secukinumab improves active psoriatic
arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5
study." (2018). Journal Articles and Abstracts. 430.
https://digitalcommons.psjhealth.org/publications/430

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Journal
Articles and Abstracts by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.

Authors

Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul
Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, and Ken Abrams

This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/publications/430

Clinical and epidemiological research

Extended report

Secukinumab improves active psoriatic arthritis
symptoms and inhibits radiographic progression:
primary results from the randomised, double-blind,
phase III FUTURE 5 study
Philip Mease,1 Désirée van der Heijde,2 Robert Landewé,3 Shephard Mpofu,4
Proton Rahman,5 Hasan Tahir,6 Atul Singhal,7 Elke Boettcher,8 Sandra Navarra,9
Karin Meiser,4 Aimee Readie,10 Luminita Pricop,10 Ken Abrams10
Handling editor Josef S
Smolen
►► Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2017-212687).

For numbered affiliations see
end of article.
Correspondence to
Prof Philip Mease,
Rheumatology Research,
Swedish Medical Center, Seattle,
WA 98122, USA;
pmease@philipmease.com
Received 13 November 2017
Revised 30 January 2018
Accepted 19 February 2018
Published Online First
17 March 2018

Abstract
Objectives To evaluate the effect of subcutaneous
(s.c.) secukinumab, an interleukin-17A inhibitor,
on clinical signs and symptoms and radiographic
progression in patients with psoriatic arthritis (PsA).
Methods Adults (n=996) with active PsA were
randomised 2:2:2:3 to s.c. secukinumab 300 mg
or 150 mg with loading dose (LD), 150 mg without
LD or placebo. All groups received secukinumab or
placebo at baseline, weeks 1, 2 and 3 and then every
4 weeks from week 4. The primary endpoint was the
proportion of patients achieving an American College
of Rheumatology 20 (ACR20) response at week 16.
Results Significantly more patients achieved an
ACR20 response at week 16 with secukinumab
300 mg with LD (62.6%), 150 mg with LD (55.5%)
or 150 mg without LD (59.5%) than placebo (27.4%)
(p<0.0001 for all; non-responder imputation).
Radiographic progression, as measured by van der
Heijde-modified total Sharp score, was significantly
inhibited at week 24 in all secukinumab arms versus
placebo (p<0.01 for 300 mg with LD and 150 mg
without LD and p<0.05 for 150 mg with LD; linear
extrapolation). Adverse event rates at week 24 were
similar across treatment arms: 63.1% (300 mg with
LD), 62.7% (150 mg with LD), 61.1% (150 mg without
LD) and 62.0% (placebo). No deaths or new safety
signals were reported.
Conclusion S.c. secukinumab 300 mg and 150 mg
with and without LD significantly improved clinical
signs and symptoms and inhibited radiographic
structural progression versus placebo at week 24 in
patients with PsA.
Trial registration number NCT02404350; Results.
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Psoriatic arthritis (PsA) is a chronic, inflammatory
disease characterised by peripheral arthritis, axial
disease, dactylitis, enthesitis and skin and nail
psoriasis.1 2 It can have a substantial impact on
quality of life and work productivity,3 with many
patients experiencing irreversible joint damage
and disability.1 4 Indeed, bone erosions occur in
approximately half of patients within 2 years.5
Enhanced understanding of the pathophysiology of PsA has aided the development of

targeted therapies to manage its signs and symptoms. The proinflammatory cytokine interleukin
(IL)-17A mediates multiple biological functions
that result in joint and entheseal inflammation,
damage and tissue remodelling, which are characteristic of PsA.6–8 Recommendations from the
European League Against Rheumatism (EULAR)9
and the Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA)10
recognise targeting IL-17A as a therapeutic
strategy to manage all the main clinical domains
of PsA.
Secukinumab, a fully human monoclonal antibody
that selectively neutralises IL-17A,11 is approved in
many countries for the treatment of PsA, psoriasis
and ankylosing spondylitis. There is now an extensive body of evidence involving more than 2700
patients demonstrating the efficacy of secukinumab
in PsA.12–18 Data from the phase III studies, FUTURE
1 and FUTURE 2, have shown that secukinumab
provides rapid and significant improvements in the
signs and symptoms of PsA that are sustained for
up to 3 years of therapy.12–18 These clinical benefits
have been observed in patients naïve to biological
therapy and in those with an intolerance or inadequate response to agents targeting tumour necrosis
factor (TNF).9 10 13–18 Data from FUTURE 1 have
shown that secukinumab significantly inhibits joint
structural damage through 24 weeks,13 with benefits maintained out to 2 years.17 FUTURE 1 used
an intravenous loading followed by subcutaneous
(s.c.) dosing regimen for secukinumab and did not
evaluate a dose higher than 150 mg.13 FUTURE 2
used s.c. loading and maintenance dosing of secukinumab 300, 150 and 75 mg14 (the 300 and 150 mg
dosing regimens were subsequently adopted as the
approved regimens in PsA), but it did not examine
radiographic progression and, until now, these data
have been lacking. Here, we report primary results
from the ongoing FUTURE 5 study, the largest
randomised, controlled study to date of a biologic
in PsA. The study was designed to evaluate the
impact of s.c. secukinumab 300 and 150 mg on clinical signs and symptoms and radiographic progression as well as evaluating the short-term benefit of
the loading regimen. This trial is ongoing and will
provide long-term data out to 2 years.
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Methods
Study design and participants

FUTURE 5 (NCT02404350) is a randomised, double-blind,
placebo-controlled, parallel-group phase III trial. The study
design is shown in online supplementary figure 1. The study was
conducted in accordance with the principles of the Declaration
of Helsinki.19 Patients provided written informed consent before
study-related procedures were undertaken.
Patients were aged ≥18 years and met the ClASsification
criteria for Psoriatic ARthritis2 at screening, with symptoms of
moderate-to-severe PsA for at least 6 months: ≥3 tender joints
and ≥3 swollen joints despite ≥4 weeks of treatment with
non-steroidal anti-inflammatory drugs (NSAIDs), or an intolerance to them, and active or documented history of plaque
psoriasis or psoriatic nail changes. Concomitant corticosteroids
(≤10 mg/day prednisone or equivalent), NSAIDs and methotrexate (≤25 mg/week) were allowed, provided the dose was
stable and remained so for the first 24 weeks of the study.
Patients who had previously used anti-TNF agents could enrol if
they had experienced an inadequate response or stopped treatment due to safety or intolerance (anti-TNF-IR). Patients taking
anti-TNF therapy and/or a disease-modifying antirheumatic drug
other than methotrexate required a washout ranging from 4 to
10 weeks before randomisation, depending on the prohibited
treatment used. Key exclusion criteria included active/history of
ongoing infection, prior use of a biologic other than an anti-TNF
agent, use of ≥3 anti-TNF agents and active inflammatory
disease other than PsA.

Treatment and randomisation

Following a screening period of up to 10 weeks, Interactive
Response Technology was used to randomly assign eligible
patients in a 2:2:2:3 ratio to one of four treatment groups:
secukinumab 300 mg with loading dose (LD), secukinumab
150 mg with LD, secukinumab 150 mg without LD or placebo,
all administered s.c. (online supplementary figure 1). Patients
self-administered their own treatment using prefilled syringes at
baseline, weeks 1, 2 and 3 followed by treatment every 4 weeks
from week 4. Patients in the secukinumab 150 mg without LD
arm were administered placebo at weeks 1, 2 and 3 to conceal
treatment allocation. At week 16, patients in the placebo arm
with <20% improvement from baseline in tender and swollen
joint counts (SJCs) were switched in a double-blind manner to
receive s.c. secukinumab 300 mg or 150 mg, preassigned at original randomisation. Remaining patients in the placebo arm were
switched to blinded secukinumab 300 mg or 150 mg at week 24.
Randomisation was stratified according to previous anti-TNF
therapy use, with patients being anti-TNF-naïve (planned enrolment about 70%) or anti-TNF-IR. Patients, investigators and
assessors remain masked to the treatment assignment until all
patients reach week 52.

Outcomes

The primary efficacy endpoint was the proportion of patients
with an American College of Rheumatology 20 (ACR20)
response at week 16. The key secondary hierarchical endpoint
was radiographic structural progression at week 24, as measured
by change from baseline in van der Heijde-modified total Sharp
score (vdH-mTSS), which ranges from 0 to 528 (higher scores
indicating more articular damage)20 based on independent assessments of hand/wrist/foot radiographs obtained at baseline, week
16 (non-responders) and week 24 by two central blinded readers
(plus an adjudicator if required). Other hierarchical secondary

endpoints were assessed at week 16 and included: proportion of patients achieving a 75% or 90% improvement from
baseline in the Psoriatic Area and Severity Index (PASI75 and
PASI90, respectively);21 proportion of patients with an ACR50
response; change from baseline on the Health Assessment Questionnaire-Disability Index (HAQ-DI scores range from 0 to 3
with higher scores indicate greater disability);22 change from
baseline in the 28-joint Disease Activity Score using C reactive
protein (DAS28-CRP, with higher scores indicating more active
disease);23 and resolution of enthesitis and dactylitis. Definitions
of the ACR20 response and secondary points used in the study
are provided in the online supplementary methods.
Prespecified exploratory endpoints of ACR70 response, the
proportion of patients with no structural progression (change
from baseline in vdH-mTSS ≤0.5) at week 24 and both the
primary endpoint (ACR20 at week 16), change from baseline
vdH-mTSS at week 24 by prior use of anti-TNF therapy and
the proportion of patients achieving minimal disease activity
(MDA) are also reported. MDA is assessed as five of the seven
following: ≤1 tender joint count, ≤1 SJC, PASI≤1 or body
surface area (BSA)≤3%, patient pain visual analogue score
(VAS)≤15, patient global assessment of disease activity VAS≤20,
HAQ-DI≤0.5, tender entheseal points≤1.24 Disease Activity
index for PSoriatic Arthritis (DAPSA) was analysed posthoc.
DAPSA is a continuous index, calculated by summing of individual scores for: (1) tender joint count (TJC), (2) SJC, (3)
patient global assessment, (4) patient assessment of pain and
(5) CRP level, using 66/68 joint counts.25 DAPSA ranges from
0 to 164; DAPSA remission (REM; range 0–4) and low disease
activity (LDA; range 5–14) were assessed. Overall safety and
tolerability of secukinumab over the 24 weeks was assessed by
monitoring adverse events (AEs), serious AEs (SAEs), laboratory
assessments and vital signs.

Statistical analyses

Sample sizes were calculated based on an overall two-sided 5%
type I error rate. As three secukinumab regimens were tested
versus placebo for ACR20, the type I error was separated into
a 1.67% two-sided for each comparison. Based on ACR20
response rates of previous studies,14 a sample size of 220 patients
in each secukinumab group, and 330 in the placebo group was
estimated to provide around 99% power (for all three dose regimens) to detect a treatment difference in the primary endpoint
(ACR20 at week 16) based on Fisher’s exact test.
For the key secondary endpoint, radiographic structural
progression (vdH-mTSS), a treatment difference of 0.52 and
SD of 1.13 with active treatment and 2.44 with placebo were
observed in historical data.13 Based on these assumptions, there
is 83% power to detect a treatment difference using Satterthwaite t-test.
A sequential hierarchical testing method (online supplementary figure 2) was used to maintain the familywise type I error
rate at 5% across the primary and ranked secondary specified
endpoints. P values were calculated as 2-sided. Patients were
analysed according to randomised treatment.
Statistical analyses were based on logistic regression for binary
efficacy variables (eg, ACR20/50/70 and so on), non-parametric analysis of covariance for radiographic data (if baseline
and ≥1 postbaseline radiographic assessments were available)
and mixed-effects models for repeated measures (MMRM) for
continuous variables (eg, DAS28-CRP, HAQ-DI). All models
fitted included anti-TNF status, weight and the corresponding
baseline value as a covariate as well as treatment as a factor (time,
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treatment by time and baseline by time interaction were also
used for MMRM models). Missing values and placebo patients
rescued at week 16 were imputed as non-responders for binary
endpoints (rescue penalty), linear extrapolation was applied for
radiographic data (if baseline and week 16 values were available)
and the missing at random assumption of the MMRM analysis
was applied for continuous endpoints.
Safety endpoints were assessed for all patients who
received ≥1 dose of study drug and were summarised descriptively. Patients were evaluated according to the treatment they
received.

Results
Patients

A total of 996 patients were randomly assigned to receive secukinumab 300 mg with LD (n=222), secukinumab 150 mg with
LD (n=220), secukinumab 150 mg without LD (n=222) or
placebo (n=332). At week 24, a total of 66 (6.9%) patients had
discontinued, with the greatest number (n=37) coming from
the placebo group. The most common reason for discontinuation was patient/guardian decision (3.2% overall; 5.7% placebo,
3.2% 150 mg without LD and 1.4% for both 150 mg and 300 mg
with LD) followed by AEs (1.6% overall; 2.7% placebo, 0.9%

Table 1

150 mg each with and without LD, and 1.4% 300 mg with LD).
Patient disposition is shown in online supplementary figure 3.
Demographics and baseline characteristics were balanced
between treatment arms (table 1). Overall, the mean age was
48.8 years, 49.8% were female and the mean time since PsA
diagnosis was 6.6 years. At baseline, 70.4% of patients were
anti-TNF-naïve and 50.1% were receiving concomitant methotrexate. Approximately half (51.6%) of the patients had psoriasis
affecting ≥3% of their BSA. Enthesitis was present in 60.4%
and dactylitis in 39.1% of patients. Mean swollen and tender
joint counts were 11.5 and 21.0, respectively and mean HAQ-DI
score was 1.3.

Efficacy

The primary endpoint was met with all secukinumab doses.
ACR20 response rates at week 16 were significantly higher
with secukinumab 300 mg with LD (62.6%), 150 mg with LD
(55.5%) or 150 mg without LD (59.5%) than placebo (27.4%;
p<0.0001 for all doses vs placebo; figure 1, online supplementary table 1 and table 2). ACR50/70 response rates at week
16 were also significantly higher with all secukinumab doses
versus placebo (figure 1 and online supplementary table 1).
ACR20/50/70 response rates at week 16 were numerically higher

Demographics and baseline characteristics for the randomised set

Characteristic

Secukinumab
300 mg with LD
(n=222)

Secukinumab
150 mg with LD
(n=220)

Secukinumab
150 mg without LD Placebo
(n=222)
(n=332)

Total
(n=996)
48.8 (12.4)

Age (years), mean (SD)

48.9 (12.8)

48.4 (12.9)

48.8 (11.8)

49.0 (12.1)

Female, n (%)

114 (51.4)

109 (49.5)

102 (45.9)

171 (51.5)

496 (49.8)

Weight (kg)

81.9 (16.9)

83.3 (19.6)

84.1 (20.5)

84.1 (19.6)

83.4 (19.2)

  White

184 (82.9)

178 (80.9)

180 (81.1)

274 (82.5)

816 (81.9)

  Asian

24 (10.8)

29 (13.2)

27 (12.2)

33 (9.9)

113 (11.3)
10 (1.0)

Race, n (%)

 American Indian or Alaska Native

1 (0.5)

1 (0.5)

6 (2.7)

2 (0.6)

  Black or African American

1 (0.5)

0 (0.0)

0 (0.0)

5 (1.5)

6 (0.6)

  Unknown

0 (0.0)

0 (0.0)

2 (0.9)

2 (0.6)

4 (0.4)

  Other

12 (5.4)

12 (5.5)

7 (3.2)

16 (4.8)

47 (4.7)

Time since first diagnosis of psoriatic disease (years), mean (SD)

6.7 (8.3)

6.7 (7.1)

6.2 (6.1)

6.6 (7.6)

6.6 (7.3)

  0

154 (69.4)

155 (70.5)

158 (71.2)

234 (70.5)

701 (70.4)

  1

45 (20.3)

43 (19.5)

44 (19.8)

65 (19.6)

197 (19.8)

Number of prior anti-TNF therapies, n (%)

 ≥2
Methotrexate use at randomisation, n (%)
Systemic glucocorticoid at randomisation, n (%)

23 (10.4)

22 (10.0)

20 (9.0)

33 (9.9)

98 (9.8)

112 (50.5)

108 (49.1)

120 (54.1)

159 (47.9)

499 (50.1)

34 (15.3)

44 (20.0)

37 (16.7)

53 (16.0)

168 (16.9)

Patients with specific disease characteristics, n (%)
 Psoriasis affecting≥3% of BSA

110 (49.5)

125 (56.8)

117 (52.7)

162 (48.8)

514 (51.6)

 Presence of enthesitis

140 (63.1)

141 (64.1)

129 (58.1)

192 (57.8)

602 (60.4)

 Presence of dactylitis

82 (36.9)

80 (36.4)

103 (46.4)

124 (37.3)

389 (39.1)

Disease and quality of life scores, mean (SD)
 Tender joint count (78 joints)

19.8 (15.1)

21.2 (15.9)

21.8 (16.0)

21.2 (16.2)

21.0 (15.8)

 Swollen joint count (76 joints)

10.0 (8.0)

12.1 (10.5)

11.9 (10.3)

11.7 (10.8)

11.5 (10.1)

 DAS28-CRP score

4.5 (1.0)

4.7 (1.0)

4.6 (1.1)

4.6 (1.1)

4.6 (1.1)

 HAQ-DI score

1.2 (0.6)

1.3 (0.6)

1.3 (0.7)

1.3 (0.6)

1.3 (0.6)

 vdH-mTSS

12.9 (23.7)

13.6 (25.9)

15.3 (37.5)

15 (38.2)

 PsA pain, VAS 0–100 mm

52.8 (24.8)

56.5 (22.8)

54.5 (22.9)

53.6 (24.5)

54.3 (23.9)

–

 Patients’ global assessment of disease activity, VAS 0–100 mm

55.0 (22.8)

53.9 (22.6)

54.6 (23.5)

52.5 (22.2)

53.9 (22.7)

 Physician’s global assessment of disease activity, VAS 0–100 mm

55.4 (18.3)

57.7 (18.6)

57.3 (19.2)

54.3 (20.3)

55.9 (19.3)

BSA, body surface area; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; LD, loading dose; PsA,
psoriatic arthritis; TNF, tumour necrosis factor; VAS, visual analogue scale; vdH-mTSS, van der Heijde-modified total Sharp score.
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Figure 1 (A) ACR20, (B) ACR50 and (C) ACR70 response rates from baseline up to week 24a in the overall population and by anti-TNF status.
*P<0.0001; †p<0.001; §p<0.01; ‡p<0.05 unadjusted p values versus placebo (Statistical analysis was based on logistic regression. Missing values
and placebo patients rescued at week 16 were imputed as non-responders.) aThe primary endpoint was ACR20 response in the overall population at
week 16. ACR20/50/70, ≥20/50/70% improvement from baseline in American College of Rheumatology response criteria; anti-TNF-IR, intolerance or
inadequate response to antitumour necrosis factor therapy.
in anti-TNF-naive than anti-TNF-IR patients for all secukinumab
doses. All secondary hierarchical endpoints were significant for
secukinumab versus placebo at week 16, except for enthesitis and
dactylitis resolution for the 150 mg without LD group (table 2,
figure 2 and online supplementary table 2).
Mean changes from baseline in vdH-mTSS demonstrated
significant inhibition of radiographic structural progression at
week 24 in all secukinumab groups versus placebo: 0.08 (300 mg
with LD; p<0.01), 0.17 (150 mg with LD; P<0.05), –0.09 (150
mg without LD; p<0.05) versus 0.50 (placebo; figure 3, online
supplementary table 3 and table 2). The proportion of patients

with no radiographic structural progression at week 24, defined
as ≤0.5 change from baseline in vdH-mTSS, was higher across
all secukinumab dose regimens than placebo: 191/217 (88.0%)
patients in the secukinumab 300 mg with LD group, 170/213
(79.8%) in the 150 mg with LD group and 176/210 (83.8%) in
the 150 mg without LD group versus 218/296 (73.6%) in the
placebo group (online supplementary figure 4).
The 300 mg secukinumab dose provided numerically better
efficacy in all hierarchical endpoints versus the 150 mg regimens, with the strongest treatment difference observed for
psoriasis improvement. PASI 75 response rates at week 16 were
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Table 2

Comparison of secukinumab versus placebo at week 16 for prespecified hierarchical endpoints
Secukinumab 300 mg
with LD
(n=222)

Secukinumab 150 mg
with LD
(n=220)

Secukinumab
150 mg without LD
(n=222)

Placebo
(n=332)

62.6***

55.5***

59.5***

27.4

Primary endpoint
 ACR20 response (%)
Prespecified secondary endpoints
 vdH-mTSS structural progression (mean change from BL)†

0.08**

0.17*

−0.09*

0.50

 PASI 75 response (%)‡

70.0*

60.0*

58.1*

12.3

 PASI 90 response (%)‡

53.6*

36.8*

31.6*

9.3

 ACR50 response (%)

39.6*

35.9*

32.0*

8.1

 HAQ-DI score (LS mean change from BL)

−0.55*

−0.44*

−0.45*

−0.21

 DAS28-CRP score (LS mean change from BL)

−1.49*

−1.29*

−1.29*

−0.63

 Enthesitis resolution (%)§

55.7*

54.6*

41.9

35.4

 Dactylitis resolution (%)¶

65.9*

57.5*

56.3

32.3

*P<0.05; **p<0.01; ***p<0.0001 unadjusted p values versus placebo are shown for endpoints that were significant in the hierarchical testing.
†Week 24 data.
‡Data from patients with baseline psoriasis affecting ≥3 BSA.
§Data from patients with enthesitis at baseline.
¶Data from patients with dactylitis at baseline.
ACR20, American College of Rheumatology 20; BL, baseline; BSA, body surface area; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Health
Assessment Questionnaire-Disability Index; LD, loading dose; LS, least squares; PASI, Psoriasis Area and Severity Index; vdH-mTSS, van der Heijde-modified total Sharp score.

70.0% with 300 mg with LD, 60.0% with 150 mg with LD,
58.1% with 150 mg without LD and 12.3% with placebo; corresponding PASI 90 responses rates were 53.6%, 36.8%, 31.6%
and 9.3%, respectively. Treatment responses were greater in antiTNF-naïve patients than in anti-TNF-IR patients (Figures 1,3).
In the 150 mg groups, patients receiving LD generally had an
earlier onset of response and numerically greater efficacy versus
patients without LD (figure 1).
The proportion of patients achieving MDA at week 16 were
33.0% with secukinumab 300 mg, 28.2% with 150 mg with
LD, 23.0% with 150 mg without LD and 8.4% with placebo
(p<0.001 for all secukinumab doses versus placebo; online
supplementary figure 5). The proportion of patients achieving
DAPSA REM/LDA states at week 16 were 15.2%/37.4% with
secukinumab 300 mg, 13.4%/27.8% with 150 mg with LD,
9.0%/34.8% with 150 mg without LD and 2.3%/18.9% with
placebo (online supplementary figure 5).

Safety
Exposure and safety are reported in table 3. The duration of
exposure over the 24 weeks was higher for secukinumab (329.7
patient-years) than placebo (122.7 patient-years) due to 158
patients in the placebo group switching to secukinumab at
week 16. The most commonly reported AEs represented upper
respiratory tract infections; other common AEs are reported
in table 3. No deaths or major adverse cardiac events were
reported. Non-fatal SAE rates were low overall and similar for
secukinumab (3.0%) and placebo (3.6%). Most SAEs represented single events with no discernible pattern.
Selected SAEs of interest included: one report of suicidal
thoughts in a patient with a history of anxiety who continued
in the study without further episodes; one anaphylactic reaction after the second secukinumab dose, which resulted in
patient discontinuation; one new diagnosis of ulcerative
colitis in a secukinumab patient with no prior gastrointestinal

Figure 2 Resolution of enthesitis and dactylitis in the overall population from baseline up to week 24a.*P<0.0001; †p<0.001; §p<0.01;
‡p<0.05 unadjusted p values versus placebo. (Statistical analysis was based on logistic regression. Missing values and placebo patients rescued at
week 16 were imputed as non-responders.) aResolution of dactylitis and enthesitis were not significant for secukinumab 150 mg without load in
hierarchical testing.
894
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Figure 3 Change in vdH-mTSS from baseline at week 24 (non-parametric ANCOVA-linear extrapolation in the overall population and by antiTNF status. †P<0.001; §p<0.01; ‡p<0.05 unadjusted p values versus placebo (Statistical analysis was based on a non-parametric ANCOVA. Linear
extrapolation was applied if a baseline and week 16 value were available). ANCOVA, analysis of covariance; anti-TNF-IR, intolerance or inadequate
response to antitumour necrosis factor therapy; LD, loading dose; vdH-mTSS, van der Heijde-modified total Sharp score.

Table 3

Exposure and rates of deaths, discontinuations, AEs, SAEs and selected AEs and SAEs of interest up to week 24†
Secukinumab
300 mg with LD
(n=222)

Secukinumab
150 mg with LD
(n=220)

Secukinumab
150 mg without LD
(n=222)

Any
secukinumab
(n=822)

Placebo
(n=332)

 Patient-years

102.0

101.8

101.2

329.7

122.9

 Days (mean)

167.8

169.0

166.5

146.5

135.0

 Death, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Discontinuation due to AE, n (%)

3 (1.4)

4 (1.8)

3 (1.4)

11 (1.3)

7 (2.1)

 Non-fatal SAE, n (%)

7 (3.2)

9 (4.1)

6 (2.7)

25 (3.0)

12 (3.6)

 Number of patients with any AE, n (%)

140 (63.1)

138 (62.7)

136 (61.3)

463 (56.3)

206 (62.0)

 Viral upper respiratory tract infection

14 (6.3)

15 (6.8)

13 (5.9)

44 (5.4)

29 (8.7)

 Upper respiratory tract infection

7 (3.2)

17 (7.7)

14 (6.3)

38 (4.6)

11 (3.3)

 Dyslipidaemia

8 (3.6)

4 (1.8)

8 (3.6)

23 (2.8)

11 (3.3)

 Headache

5 (2.3)

9 (4.1)

8 (3.6)

23 (2.8)

13 (3.9)

 Hypertension

8 (3.6)

5 (2.3)

9 (4.1)

22 (2.7)

10 (3.0)

 Diarrhoea

9 (4.1)

4 (1.8)

7 (3.2)

21 (2.6)

22 (6.6)

 Hypercholesterolaemia

3 (1.4)

9 (4.1)

8 (3.6)

20 (2.4)

2 (0.6)

 Urinary tract infection

6 (2.7)

8 (3.6)

6 (2.7)

20 (2.4)

8 (2.4)

 Candida infection

1 (0.5)

0 (0.0)

0 (0.0)

1 (0.1)

0 (0.0)

 Oral candidiasis

2 (0.9)

1 (0.5)

0 (0.0)

3 (0.4)

1 (0.3)

 Vulvovaginal candidiasis

1 (0.5)

2 (0.9)

0 (0.0)

3 (0.4)

1 (0.3)

 Injections site reactions

6 (2.7)

5 (2.3)

3 (1.4)

15 (1.8)

4 (1.2)

 Crohn’s disease

0 (0.0)

0 (0.0)

1 (0.5)

1 (0.1)

0 (0.0)

 Ulcerative colitis

0 (0.0)

1 (0.5)

0 (0.0)

1 (0.1)

0 (0.0)

 Neoplasms benign, malignant and unspecified

0 (0.0)

0 (0.0)

1 (0.5)§

2 (0.2)¶

0 (0.0)

Variable
Exposure

Death and AEs

Most common AEs, n (%)‡

Selected AEs of interest, n (%)

Selected SAEs of interest, n (%)

†Up to the data cut-off point for interim analysis.
‡AEs that occurred at an incidence rate of >2% in the ‘any secukinumab’ group. Any secukinumab group represents each originally randomised secukinumab patient plus
patients who switched to active treatment at week 16 due to non-response.
§Bladder neoplasm reported as an non-serious AE (day 34).
¶Includes one case of melanoma (day 139) in a placebo patient switched to secukinumab (day 113).
AE, adverse event; LD, loading dose; SAE, serious adverse event.
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medical history and who remained in the study and one case
of Crohn’s disease in a patient with a history of colitis. There
was one mild, non-serious exacerbation of Crohn’s disease in
a secukinumab-treated patient who continued on study treatment and remained in the study; the event was resolved at the
time of reporting.
Reports of Candida infections included: one case of oral
thrush (300 mg with LD), four cases of oral candidiasis (one
in 150 mg with LD; two in 300 mg with LD; one in placebo)
and four cases of vulvovaginal candidiasis (two in 150 mg
with LD; one in 300 mg; one in placebo). These were of mild
severity, except one moderately severe vulvovaginal candida
infection; all resolved with standard therapy. No systemic
fungal infections or newly diagnosed tuberculosis infections
were reported, and incidences of injection site reactions were
low across all groups.

Discussion

FUTURE 5 is the largest randomised phase III trial to date of a
biologic in PsA. In this study, s.c. administration of secukinumab
300 mg and 150 mg provided rapid and significant improvement
versus placebo in most clinical domains of PsA and inhibited
radiographic progression at week 24.
The primary endpoint, ACR20 response at week 16, was met
for all secukinumab regimens, and secondary endpoints were
significant for all secukinumab doses except for enthesitis and
dactylitis resolution in the 150 mg without LD group. These
results confirm and extend previous findings relating to the efficacy of secukinumab in PsA.12–18 In addition, clinical response
rates (ACR20/50/70) at week 16 were higher in anti-TNF-naive
patients than in those who were anti-TNF-IR for all secukinumab doses.
These data provide the first evidence that s.c. secukinumab
loading and maintenance dosing regimens and the higher dose
of 300 mg significantly inhibit joint structural damage in PsA.
More patients who received secukinumab versus those who
received placebo had no radiographic progression through week
24. Inhibition of radiographic progression was observed in both
anti-TNF-naïve and anti-TNF-IR patients, although statistical
significance was not reached in the anti-TNF-IR population. The
lack of significance could be affected by a number of factors,
including the relatively small number of anti-TNF-IR patients
and the heterogeneity of this subpopulation, which comprised
patients who previously failed anti-TNF treatment for any one of
several reasons, including lack of primary or secondary efficacy,
intolerance or safety concerns.26 This study was limited in that
it was not designed to identify a difference between doses or
to assess differences in response according to previous anti-TNF
use.
Patients enrolled in this study had a long duration of disease
(mean around 6.5 years) and very active disease as evidenced
by the relatively high tender and swollen joint scores and the
large proportion of patients with enthesitis and dactylitis at
baseline. Additionally, around 30% of patients had previously
received one or more anti-TNF treatments before entering
this trial. While anti-TNF agents have been shown to improve
outcomes in PsA,27–31 many patients experience inadequate
disease control, treatment intolerance or loss of response over
time.1 32 In agreement with previous studies,9 10 13–18 secukinumab treatment in FUTURE 5 was shown to be efficacious
in both anti-TNF-naïve and anti-TNF-IR patients, with clinical
responses generally being higher in anti-TNF-naïve patients.
These results confirm that secukinumab is a suitable treatment
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option for biologic-naïve patients and those who have previously failed anti-TNF therapy.
The secukinumab 300 mg dose consistently provided numerically better responses versus the 150 mg dose, with or without
LD, in clinical endpoints such as ACR20/50/70, resolution of
enthesitis and dactylitis, HAQ-DI, DAS28-CRP, PASI 75 and PASI
90, particularly in anti-TNF-IR patients. Data from FUTURE 5
also demonstrate the benefit of a loading regimen in terms of
providing an earlier onset of action, especially on higher efficacy
endpoints such as ACR50/70, dactylitis and in the treatment of
psoriasis symptoms, as indicated by PASI 75 and PASI 90, and
in the proportion of patients achieving MDA and DAPSA-REM.
The safety profile was consistent with that previously reported
for PsA12–18 and psoriasis.32 The types and incidences of most
AEs with secukinumab were similar to those for placebo for the
entire 24-week treatment period, without evidence of dose-dependency. The rate of Candida infections was higher with
secukinumab treatment than with placebo; this is consistent
with previous reports13 14 and considered to be related to the
role of IL-17 in mucocutaneous defence against Candida infections.33 No systemic fungal infections were reported. All cases
of Candida infection resolved with standard oral therapy and
patients continued in the study.
This study demonstrated that s.c. secukinumab 300 mg and
150 mg provided significant inhibition of radiographic progression, and has demonstrated the benefit of a LD regimen (regardless of the dose), particularly when aiming for higher levels of
response and faster outcomes in joint and skin endpoints. The
safety profile of secukinumab was consistent with previous
reports, with no new safety signals observed.12–18 FUTURE 5
confirms and extends the results of previous data demonstrating
the efficacy of s.c. administration of secukinumab in achieving
comprehensive treatment goals in PsA.
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